Arsanis (ASNS) Issues Earnings Results

Arsanis (NASDAQ:ASNS) announced its earnings results on Friday. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02), MarketWatch Earnings reports.

ASNS traded down $0.06 during mid-day trading on Friday, reaching $1.37. 857,225 shares of the company traded hands, compared to its average volume of 198,372. The firm has a market cap of $19.75 million and a PE ratio of -0.08. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.20. Arsanis has a 52-week low of $1.25 and a 52-week high of $28.69.

A number of equities research analysts have weighed in on ASNS shares. ValuEngine upgraded shares of Arsanis from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research lowered shares of Arsanis from a “buy” rating to a “hold” rating in a research note on Monday, October 15th. Finally, Piper Jaffray Companies decreased their target price on shares of Arsanis to $2.50 and set a “neutral” rating for the company in a research note on Monday, August 13th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Arsanis currently has a consensus rating of “Hold” and a consensus target price of $14.88.

WARNING: “Arsanis (ASNS) Issues Earnings Results” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/11/10/arsanis-asns-issues-earnings-results.html.

About Arsanis

Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.

Featured Article: Earnings Per Share (EPS)

Receive News & Ratings for Arsanis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arsanis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply